T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Recruiting now · Phase 1
Conditions studied: Tumor, Solid
In brief
An open label, two-cohort, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301V and NW-301D in subjects with advanced solid tumor.
Key facts
- Study ID
- NCT06484556
- Run by
- Tao Zhang
- People needed
- 9
- Starts
- 2024-06-19
- Expected to finish
- 2027-06-30
- Last updated by the study team
- 2025-07-31
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Wuhan Union Hospital — Wuhan, Hubei, China (enrolling)
- Wuhan Union Hospital — Wuhan, Hubei, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.